title: Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
abstract: The proportion of patients with cancers who develop invasive fungal infections has increased dramatically over the past few decades. Most of these infections are diagnosed in patients with hematological malignancies, mainly in patients with acute myeloid leukemia and those undergoing allogeneic hematopoietic stem cell transplantation. For years deoxycolate amphotericin B has been considered the drug of choice for the treatment of invasive aspergillosis, but it has been outclassed by its lipid formulations and new triazoles (i.e. voriconazole), that produced better response rates; nonetheless recovery from neutropenia remains the most important factor influencing outcome.
authors.affiliation: Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy. lpagano@rm.unicatt.it
authors.forename: L
authors.initials: L
authors.lastname: Pagano
authors.forename: C G
authors.initials: CG
authors.lastname: Valentini
authors.forename: L
authors.initials: L
authors.lastname: Fianchi
authors.forename: M
authors.initials: M
authors.lastname: Caira
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy / Q000382:microbiology*; D011743:Pyrimidines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; C068538:liposomal amphotericin B; D000666:Amphotericin B; D065819:Voriconazole